Lung biomarkers and methods of use thereof
Inventors
Blume, John E. • Manning, William C. • Troiano, Gregory • Siddiqui, Asim • Ma, Philip • Farokhzad, Omid C.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11664092-B2
Publication Date
2023-05-30
Expiration Date
Abstract
Disclosed herein are biomarkers associated with a disease state such as lung cancer, and methods of discovering or using biomarkers. Also disclosed herein are classifiers built on biomarkers and methods of detecting the disease state in samples from subjects. The method may include obtaining a data set that includes protein information from a biofluid sample, and may involve using a classifier to identify the sample as indicative of a healthy state, a disease state, or a comorbidity.
Core Innovation
The invention obtains a data set comprising protein information from biomolecule coronas that correspond to physicochemically distinct particles incubated with a biofluid sample from a subject suspected of having a cancer state or a comorbidity of the cancer state. The protein information comprises a concentration or amount of serine protease HTRA1, Peroxidasin homolog (PXDN), Anthrax toxin receptor 2 (ANTR2), Versican core protein (CSPG2), Anthrax toxin receptor 1 (ANTR1), Palmitoleoyl-protein carboxylesterase NOTUM (NOTUM), Cartilage intermediate layer protein 1 (CILP1), or Calpain-2 catalytic subunit (CAN2). The cancer state comprises non-small cell lung cancer (NSCLC), and the comorbidity comprises a pulmonary comorbidity.
The invention applies a classifier to the data set to identify the biofluid sample as indicative of a healthy state, the cancer state, or the comorbidity of the cancer state. The classifier distinguishes the cancer state from the comorbidity of the cancer state or distinguishes the cancer state from the healthy state, and identifies the biofluid sample as indicative of the cancer state.
In an alternative form, the protein information is obtained as measurements of distinct peptides of a protein group from biomolecule coronas that correspond to physicochemically distinct particles incubated with the sample. After identifying the biofluid sample as indicative of the cancer state, the method administers a treatment to the subject, where the treatment comprises resection surgery to remove the cancer, an anti-cancer agent, or radiation therapy.
Claims Coverage
Two independent claims are present. They define a treatment method that uses biomolecule corona-derived protein information from physicochemically distinct particles, applies a classifier to distinguish NSCLC from pulmonary comorbidity or healthy state, and then administers treatment. The independent claims differ in whether the input is protein concentration or amount, or measurements of distinct peptides of a protein group.
Biomolecule corona protein information from physicochemically distinct particles
Obtaining a data set comprising protein information from biomolecule coronas that correspond to physicochemically distinct particles incubated with a biofluid sample from a subject suspected of having a cancer state or a comorbidity of the cancer state, wherein the protein information comprises a concentration or amount of HTRA1, PXDN, ANTR2, CSPG2, ANTR1, NOTUM, CILP1, or CAN2.
Classifier distinguishes NSCLC from pulmonary comorbidity or healthy state
Applying a classifier to the data set to identify the biofluid sample as indicative of a healthy state, the cancer state, or the comorbidity of the cancer state, wherein the classifier distinguishes the cancer state from the comorbidity of the cancer state or distinguishes the cancer state from the healthy state, and wherein the cancer state comprises non-small cell lung cancer (NSCLC) and the comorbidity of the cancer state comprises a pulmonary comorbidity.
Administer treatment based on classifier identification
Administering a treatment to the subject, where the treatment comprises resection surgery to remove the cancer, an anti-cancer agent, or radiation therapy.
Distinct peptide measurements from corona-associated protein group
Obtaining protein information from a biofluid sample, wherein the protein information comprises measurements of distinct peptides of a protein group, and wherein the protein information is from biomolecule coronas that correspond to physicochemically distinct particles incubated with the sample.
Classifier distinguishes NSCLC from pulmonary comorbidity or healthy state using peptide measurements
Applying a classifier to the measurements of the distinct peptides of the protein group to identify the protein information as indicative of a healthy state, a cancer state, or a comorbidity of the cancer state, wherein the classifier distinguishes the cancer state from the comorbidity of the cancer state or distinguishes the cancer state from the healthy state, and wherein the cancer state comprises non-small cell lung cancer (NSCLC) and the comorbidity of the cancer state comprises a pulmonary comorbidity.
The inventive concept is obtaining biomolecule corona-derived protein information from physicochemically distinct particles, applying a classifier to identify the sample as healthy, NSCLC, or pulmonary comorbidity by distinguishing cancer from healthy and/or comorbidity, and administering treatment including resection surgery, an anti-cancer agent, or radiation therapy. The second independent claim uses measurements of distinct peptides of a protein group as the classifier input.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?